Hepatic Markers Profile in Cytolysis and Cholestasis during Antiretroviral Treatment at the Charles de Gaulle University Hospital

Introduction: Mother-to-child transmission of HIV is a public health problem for sub-Saharan African countries. Systematic antiretroviral treatment at diagnosis is an important step in the evolution of HIV/AIDS management. However, this treatment can be the cause of hepatic adverse effects. The aim of this study was to evaluate the profile of hepatic cytolysis and cholestasis markers in children living with HIV under ARV treatment at Charles de Gaulle Pediatric University Hospital (CHUP-CDG). Materials and Methods: This was a descriptive cross-sectional study from February to June 2018 in which markers of cytolysis (AST, ALT, and LDH) and cholestasis (ALP and γGT) were studied in children living with HIV 1 undergoing ARV treatment at CHUP-CDG. Results: The markers of hepatic cytolysis, ALT, AST and LDH, were elevated in 11.63%, 13.95% and 26.74% of children on ARV treatment, respectively; as were those of hepatic cholestasis (ALP=77.91% and γGT=12.79%). Cytolysis and hepatic cholestasis were more marked in children with CD4 counts below 400/mL. In addition, when the viral load was less than 500 copies/mL and when the duration of treatment was more than 12 months, the proportions of these liver biological disorders were higher in children on ARV treatment. Conclusion: The disturbances observed on cytolysis and cholestasis markers were slightly elevated, but without serious consequences because they were mostly at low toxicity levels.